Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.56 |
| ▸ | CA6 | P23280 | 5/20 | 0.56 |
| ▸ | CA7 | P43166 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 5/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.53 |
| ▸ | CA4 | P22748 | 4/20 | 0.53 |
| ▸ | CA5A | P35218 | 4/20 | 0.53 |
| ▸ | CA3 | P07451 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL29127322 | 1.00 | CA12 (0.56) | CA12CA6CA7CA9CA14 | |
| Trientine SCHEMBL28215979 | 0.97 | CA12 (0.58) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL1565417 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL9100273 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL27525013 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL3657736 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL863599 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL18288 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL9716193 | 0.97 | CA12 (0.59) | CA12CA6CA7CA9CA14 | |
| Acetic Acid SCHEMBL7046368 | 0.94 | CA12 (0.56) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 499 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118016944-A | Water system iron-cerium flow battery | 北京化工大学 | 2024-05-10 | — | — | CN | claimed |
| EP-3694558-B1 | IL-4-FUSION FORMULATIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS | MEDICENNA THERAPEUTICS INC (CA) | 2024-04-10 | — | — | EP | claimed |
| US-20230405115-A1 | COMBINATION THERAPY OF MDNA55 AND A VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A) | MEDICENNA THERAPEUTICS, INC. (CA) | 2023-12-21 | — | — | US | claimed |
| CN-112546221-B | Tumor diagnosis and treatment medicine and preparation method and application thereof | 深圳先进技术研究院 | 2023-12-19 | — | — | CN | claimed |
| CN-116983437-A | Nondestructive image marking method and product of alpha Olig2 and application thereof | 武汉大学中南医院 | 2023-11-03 | — | — | CN | claimed |
| US-11788057-B2 | 3D label-free contactless formation of cellular structures and co-cultures through diamagnetophoresis | MCMASTER UNIVERSITY (CA) | 2023-10-17 | — | — | US | claimed |
| CN-116829184-A | Combination therapy of MDNA55 and vascular endothelial growth factor A (VEGF-A) | 梅迪塞纳医疗股份有限公司 | 2023-09-29 | — | — | CN | claimed |
| EP-4225377-A1 | COMBINATION THERAPY OF MDNA55 AND A VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A) | Medicenna Therapeutics, Inc. (CA) | 2023-08-16 | — | — | EP | claimed |
| WO-2022077102-A1 | COMBINATION THERAPY OF MDNA55 AND A VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF-A) | MEDICENNA THERAPEUTICS, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| CN-108289970-B | Formulations comprising a combination of MRI contrast agents | 通用电气医疗集团股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| WO-2001052906-A2 | MAGNETIC RESONANCE IMAGING USING CONTRAST AGENTS PRODRUGS BIOACTIVATED BY ENZYMATIC CLEAVAGE | EPIX MEDICAL, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| WO-2001049161-A2 | METHOD AND SYSTEM FOR MONITORING PANCREATIC PATHOLOGIES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-07-12 | — | — | WO | claimed |
| US-5827531-A | HAVING FIRST AND SECOND PHASES CONTAINING SOLVENTS, POLYMERS, OILS, WATER AND SURFACTANTS WITH DIFFERENT HLB VALUES, CREATING INTERFACE TO LIMIT FLUID SHEAR | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 1998-10-27 | — | — | US | claimed |
| EP-0646021-B1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALLINCKRODT MEDICAL INC (US) | 1996-11-27 | — | — | EP | claimed |
| US-5415163-A | Diagnostic and therapeutic processes utilizing magnetic resonance imaging techniques | Harms, Steven E. (US) | 1995-05-16 | — | — | US | claimed |
| EP-0646021-A1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION. | MALLINCKRODT MEDICAL INC (US) | 1995-04-05 | — | — | EP | claimed |
| CN-1094938-A | The in-vivo measurement method of the detectable biological exogenous compounds concentration of nuclear magnetic resonance, NMR | BRISTOL MYERS SQUIBB CO (US) | 1994-11-16 | — | — | CN | claimed |
| EP-0646021-A4 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION. | MALLINCKRODT MEDICAL INC (US) | 1994-10-07 | — | — | EP | claimed |
| US-5322934-A | Purification of a crude MRI agent using continuous deionization | MALLINCKRODT MEDICAL, INC. (US) | 1994-06-21 | — | — | US | claimed |
| WO-1993005820-A1 | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALLINCKRODT MEDICAL, INC. (US) | 1993-04-01 | — | — | WO | claimed |